In addition, inhibiting the glycolytic activator fructose-2,6-diphosphatase 3 (PFKFB3) in ECs not only induces normalization of tumor blood vessels, but also increases the coverage of PCs and the adhesion of tumor blood vessels to ECs, thereby increasing the delivery of chemotherapy drugs [248]. The gene discussed is PFKFB3; the disease is neoplasm.